Literature DB >> 22142751

Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).

Emily G Farrow1, Erik A Imel, Kenneth E White.   

Abstract

Familial tumoral calcinosis (TC) is a rare disorder distinguished by the development of ectopic and vascular calcified masses that occur in settings of hyperphosphatemia (hFTC) and normophosphatemia (nFTC). Serum phosphorus concentrations are relatively tightly controlled by interconnected endocrine activity at the level of the intestine, kidney, and skeleton. Discovering the molecular causes for heritable forms of hFTC has shed new light on the regulation of serum phosphate balance. This review will focus upon the genetic basis and clinical approaches for hFTC, due to genes that are related to the phosphaturic hormone fibroblast growth factor-23 (FGF23). These include FGF23 itself, an FGF23-glycosylating enzyme (GALNT3), and the FGF23 co-receptor α-Klotho (αKL). Our understanding of the molecular basis of hFTC will, in the short term, aid in understanding normal phosphate balance, and in the future, provide potential insight into the design of novel therapeutic strategies for both rare and common disorders of phosphate metabolism.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22142751      PMCID: PMC3233725          DOI: 10.1016/j.berh.2011.10.020

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  90 in total

1.  Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

Authors:  Serge L Ferrari; Jean-Philippe Bonjour; René Rizzoli
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

2.  Treatment of tumoral calcinosis with phosphorus deprivation.

Authors:  G Mozaffarian; F W Lafferty; O H Pearson
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

3.  A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis.

Authors:  Tobias Larsson; Xijie Yu; Siobhan I Davis; Mohamad S Draman; Sean D Mooney; Michael J Cullen; Kenneth E White
Journal:  J Clin Endocrinol Metab       Date:  2005-02-01       Impact factor: 5.958

4.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

5.  Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23.

Authors:  Yaacov Frishberg; Nobuaki Ito; Choni Rinat; Yuji Yamazaki; Sofia Feinstein; Itaru Urakawa; Paulina Navon-Elkan; Rachel Becker-Cohen; Takeyoshi Yamashita; Kaori Araya; Takashi Igarashi; Toshiro Fujita; Seiji Fukumoto
Journal:  J Bone Miner Res       Date:  2007-02       Impact factor: 6.741

6.  Calcitonin administration in X-linked hypophosphatemia.

Authors:  Eva S Liu; Thomas O Carpenter; Caren M Gundberg; Christine A Simpson; Karl L Insogna
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

7.  A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis.

Authors:  Kaori Araya; Seiji Fukumoto; Rebecca Backenroth; Yasuhiro Takeuchi; Kounosuke Nakayama; Nobuaki Ito; Nozomi Yoshii; Yuji Yamazaki; Takeyoshi Yamashita; Justin Silver; Takashi Igarashi; Toshiro Fujita
Journal:  J Clin Endocrinol Metab       Date:  2005-07-19       Impact factor: 5.958

8.  Type IIc sodium-dependent phosphate transporter regulates calcium metabolism.

Authors:  Hiroko Segawa; Akemi Onitsuka; Masashi Kuwahata; Etsuyo Hanabusa; Junya Furutani; Ichiro Kaneko; Yuka Tomoe; Fumito Aranami; Natsuki Matsumoto; Mikiko Ito; Mitsuru Matsumoto; Minqi Li; Norio Amizuka; Ken-Ichi Miyamoto
Journal:  J Am Soc Nephrol       Date:  2008-12-03       Impact factor: 10.121

9.  Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets.

Authors:  N Weidner; D Santa Cruz
Journal:  Cancer       Date:  1987-04-15       Impact factor: 6.860

10.  Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis.

Authors:  Tobias Larsson; Richard Marsell; Ernestina Schipani; Claes Ohlsson; Osten Ljunggren; Harriet S Tenenhouse; Harald Jüppner; Kenneth B Jonsson
Journal:  Endocrinology       Date:  2004-02-26       Impact factor: 4.736

View more
  27 in total

Review 1.  The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.

Authors:  Mark F Hoeltzel; Edward J Oberle; Angela Byun Robinson; Arunima Agarwal; Lisa G Rider
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

Review 2.  Congenital disorders of glycosylation.

Authors:  Irene J Chang; Miao He; Christina T Lam
Journal:  Ann Transl Med       Date:  2018-12

Review 3.  Pseudoxanthoma Elasticum as a Paradigm of Heritable Ectopic Mineralization Disorders: Pathomechanisms and Treatment Development.

Authors:  Qiaoli Li; Koen van de Wetering; Jouni Uitto
Journal:  Am J Pathol       Date:  2018-11-07       Impact factor: 4.307

Review 4.  Mineralization/anti-mineralization networks in the skin and vascular connective tissues.

Authors:  Qiaoli Li; Jouni Uitto
Journal:  Am J Pathol       Date:  2013-05-08       Impact factor: 4.307

5.  FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis.

Authors:  Lindsay M Coe; Sangeetha Vadakke Madathil; Carla Casu; Beate Lanske; Stefano Rivella; Despina Sitara
Journal:  J Biol Chem       Date:  2014-02-07       Impact factor: 5.157

6.  Hyperphosphatemic tumoral calcinosis caused by FGF23 compound heterozygous mutations: what are the therapeutic options for a better control of phosphatemia?

Authors:  Debora Claramunt-Taberner; Aurélia Bertholet-Thomas; Marie-Christine Carlier; Frédérique Dijoud; Franck Chotel; Caroline Silve; Justine Bacchetta
Journal:  Pediatr Nephrol       Date:  2018-03-28       Impact factor: 3.714

Review 7.  Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.

Authors:  M Chakhtoura; M S Ramnitz; N Khoury; G Nemer; N Shabb; A Abchee; A Berberi; M Hourani; M Collins; S Ichikawa; G El Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2018-06-20       Impact factor: 4.507

Review 8.  Molecular basis of Klotho: from gene to function in aging.

Authors:  Yuechi Xu; Zhongjie Sun
Journal:  Endocr Rev       Date:  2015-02-19       Impact factor: 19.871

9.  Dialysis as a Treatment Option for a Patient With Normal Kidney Function and Familial Tumoral Calcinosis Due to a Compound Heterozygous FGF23 Mutation.

Authors:  Patrícia T Goldenstein; Precil D Neves; Bruno E Balbo; Rosilene M Elias; Alexandre C Pereira; Luiz F Onuchic; Harald Jüppner; Vanda Jorgetti; Hugo Abensur; Rosa Maria Moysés
Journal:  Am J Kidney Dis       Date:  2018-03-14       Impact factor: 8.860

Review 10.  Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy.

Authors:  Young H Lim; Diana Ovejero; Kristina M Derrick; Michael T Collins; Keith A Choate
Journal:  J Am Acad Dermatol       Date:  2016-08       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.